PT Enseval Putera Megatrading Tbk., (EPMT) Fair Value & Analysis
Healthcare · ID · Market cap 6.3T IDR
Fair value as of: Jul 16, 2026
From 26 valuation models · updated 24 days ago
Share price +0.9% over the past month.
A solid business, screening 160% undervalued on our models.
What matters now
- The price is below even our cautious bear case (3,674 IDR). The market is more pessimistic than our downside scenario.
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (3,674 IDR to 7,890 IDR) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range 1,446 IDR – 2,590 IDR · fair‑value band 3,674 IDR – 7,890 IDR · the 2,370 IDR price screens below the 6,153 IDR fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
PT Enseval Putera Megatrading Tbk., (EPMT) currently trades at 2,370 IDR, while our model-based Fair Value estimate is 6,153 IDR, implying the stock looks roughly 159.6% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, PT Enseval Putera Megatrading Tbk., generated revenue of 33.7T IDR at a net margin of 2.3%. Revenue grew 9.0% year over year. It earns a return on equity of 9.7%. The balance sheet holds a net cash position of 522B IDR. Fundamentals as of Jul 16, 2026
Our scenario range runs from 3,674 IDR (bear case) to 7,890 IDR (bull case); at 2,370 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high and 13% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 160%, EPMT screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (6,153 IDR) versus Asset-Based (1,935 IDR). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 63
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Enseval Putera Megatrading Tbk., together with its subsidiaries, engages in the distribution and supply of pharmaceutical products, consumer products, medical equipment, cosmetics, and other trading products in Indonesia. The company operates through three segments: Pharmaceutical, Consumer Products, and Others.
Full company description
PT Enseval Putera Megatrading Tbk., together with its subsidiaries, engages in the distribution and supply of pharmaceutical products, consumer products, medical equipment, cosmetics, and other trading products in Indonesia. The company operates through three segments: Pharmaceutical, Consumer Products, and Others. It also trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, consumable products for hemodialysis therapy, pharmaceutical, medical equipment, and food and beverage; prescription and non-prescription medicines; veterinary products; and operates drug stores, health care clinics, and hemodialysis clinic. In addition, the company provides dental and other equipment; calibration services; distribution and logistics for consumer goods that require cold room temperature handling; transportation and warehousing service using digital platform; information services through web portals and/or digital platforms; healthcare services; end-to-end value added services; and logistic services, including chiller, cool, and ambient rooms, as well as container chiller. Further, it offers EMOS, a business-to-business (B2B) platform that offers pharmaceuticals and consumer health products; and MOSTRANS, an intelligent logistics platform that connects with shippers, transporters, and receivers. The company was formerly known as PT Arya Gupta Cempaka and changed its name to PT Enseval Putera Megatrading Tbk. in August 1993. PT Enseval Putera Megatrading Tbk. was founded in 1973 and is headquartered in Jakarta Timur, Indonesia. PT Enseval Putera Megatrading Tbk. is a subsidiary of PT Kalbe Farma Tbk.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Enseval Putera Megatrading Tbk., reported revenue of 33.0T IDR in FY2025 versus 25.7T IDR in FY2021, a compound +6.4%/yr. Reported net income was 789B IDR in FY2025, compounding −1.8%/yr from FY2021.
Watch EPMT: get an alert when its fair value changes →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare PT Enseval Putera Megatrading Tbk., with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Enseval Putera Megatrading Tbk., (EPMT) overvalued or undervalued?
What is the fair value of EPMT?
What is the quality score of EPMT?
What is the revenue of PT Enseval Putera Megatrading Tbk., (EPMT)?
What is the net profit margin of EPMT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Enseval Putera Megatrading Tbk., and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.